LOOK AT THIS IF YOU'RE INTERESTED IN:
Examining the return on investment from immunization programs against ten pathogens for ninety-four low- and middle-income countries for the period 2011–30.
HOW YOU CAN USE THIS MATERIAL:
Country policymakers and other decision makers in funding agencies can use the ROI estimates from this study to contribute to resource mobilization efforts for their national immunization programs.
OVERVIEW:
As the global community works toward establishing a new vision and strategy for the next decade, estimating the value of global investment in immunization programs is critical in the mobilization and allocation of resources to realize the full benefits of immunization. To achieve this purpose, researchers estimated the ROI of vaccines and immunization programs against ten pathogens for ninety-four low- and middle-income countries from 2011 to 2030. This study incorporated historical vaccine coverage and price data for the period 2011–17 that were unavailable in previous studies, as well as forecasts for 2018–30.
Key Points:
- Total immunization program costs for ten pathogens increase from $25.2 billion in the first decade (2011–20) to $39.9 billion in the second decade (2021–30) for ninety-four low- and middle-income countries.
- The total costs approximately average out to $24.6 per surviving infant in the first decade and $41.2 per surviving infant in the second decade, which is within the range estimated by empirical studies.
- For Gavi countries, the costs increase from $21.7 billion between 2011 and 2020 to $36.2 billion between 2021 and 2030.
- Vaccines against ten pathogens averted $681.9 billion of economic burden in ninety-four low- and middle-income countries between 2011 and 2020.
- The models predicted that an increase in coverage and the introduction of new vaccines would lead to even greater economic benefits from 2021 to 2030.